Lead-212 PSV359 Therapy for Patients With Solid Tumors

Official title

A Phase I/IIa Image-Guided, Alpha-Particle Therapy Study of [203Pb]Pb-PSV359 and [212Pb]Pb-PSV359 in Patients With Solid Tumors That Are Known to be Fibroblast Activation Protein (FAP)-Positive

Overview

Phase I/IIa image-guided, alpha-particle therapy study of \[203Pb\]Pb-PSV359 and \[212Pb\]Pb-PSV359 in patients with solid tumors that are known to be Fibroblast Activation Protein (FAP)-positive.

Detailed description

This is a prospective, multi-center open label dose finding, dose expansion study of \[212Pb\]Pb-PSV359 in subjects with a positive Fibroblast Activation Protein (FAP) imaging scan with imaging agent.

FAP is specifically expressed on the surface of cancer-associated fibroblasts in some tumor tissues and therefore is an attractive target in the diagnosis and treatment of various cancers. Lead-212 (\[212Pb\]Pb-) based peptide-radiopharmaceuticals are an emerging class of targeted alpha-particle cancer therapies that have potential to improve delivery of a highly effective form of radiation.

This study will be conducted in 2 parts:

Part 1: Dose-escalation: \[212Pb\]Pb-PSV359 is administered in escalating doses to determine the Maximum Tolerated radioactivity (MTD) Dose and potential recommended Phase 2 dose (RP2D).

Part 2: Dose-expansion: This part will enroll subjects in expansion cohorts based on the identified MTD and RP2D for the selection of \[212Pb\]Pb-PSV359 doses for further clinical development.

A Dosimetry sub-set utilizing an imaging surrogate, \[203Pb\]Pb-PSV359, has been incorporated into the study in order to assess organ biodistribution and tumor uptake of the investigational products. This sub study will also estimate radiation dosimetry and correlate uptake of the investigation products with observed toxicities and efficacy.

Interventions

• Drug [203Pb]Pb-PSV359
  \[203Pb\]Pb-PSV359 is administered by intravenous bolus injection for single-photon emission computed tomography imaging.
• Drug [212Pb]Pb-PSV359
  \[212Pb\]Pb-PSV359 is administered by intravenous infusion for treatment of FAP expressing cancers.

Primary outcome measures

• Determination of safety and tolerability of [203Pb]Pb-PSV359 [Time frame: 30 days (±1day) post dose]
• Determination of safety and tolerability of [212Pb]Pb-PSV359 [Time frame: Up to 3 years]
• To determine the recommended phase 2 dose of [212Pb]Pb-PSV359 [Time frame: Up to approximately 6 months]

Secondary outcome measures (6)

• Determination of duration of response following treatment with [212Pb]Pb-PSV359 [Time frame: Up to 3 years]
• Determination of progression free survival following treatment with [212Pb]Pb-PSV359 [Time frame: Up to 3 years]
• Determination of pharmacokinetic properties of [203Pb]Pb-PSV359 and [212Pb]Pb-PSV359 [Time frame: Up to approximately 3 yrs]
• Determination of pharmacokinetic properties of [203Pb]Pb-PSV359 and [212Pb]Pb-PSV359 [Time frame: up to approximately 3 years]
• Determination of pharmacokinetic properties of [203Pb]Pb-PSV359 and [212Pb]Pb-PSV359 [Time frame: up to approximately 3 years]
• Estimation of biodistribution of 203Pb PSV 359 using SPECT/CT scans [Time frame: Up to approximately 3 years]

Eligibility criteria

Inclusion criteria

• Aged ≥ 18 years
• Satisfactory organ function as determined by laboratory testing
• Eastern Cooperative Oncology Group performance (ECOG) status of 0 to 1
• Life expectancy > 3 months
• Progressive disease despite standard therapy or for whom no standard therapy exists
• Positive \[203Pb\]Pb-PSV359 SPECT/CT scan showing uptake of \[203Pb\]Pb-PSV359 in at least 1 known lesion on the 1-hour SPECT/ CT scan
• Histological, pathological, and/or cytological confirmation of solid tumor malignancy that is locally advanced or metastatic

Exclusion criteria

• Known hypersensitivity to the active agent or any of the excipients
• Active secondary malignancy
• Pregnancy or breastfeeding a child
• Known brain metastases
• Known active or uncontrolled infections requiring ongoing antifungals or antibiotics in the 3 days prior to enrollment
• Known medical condition which would make this protocol unreasonably hazardous for the patient
• Existence of any medical or social issues likely to interfere with study conductor that may cause increased risk to the subject or to others, e.g., lack of ability to follow radiation safety precautions
• Medical history of a condition resulting in a severe allergic reaction such as anaphylaxis or angioedema to known components of the investigational product or excipients
• Major surgery within 21 days prior to the administration of \[212Pb\]Pb-PSV359; the subject must be sufficiently recovered and stable before treatment administration
• Diagnosis of deep vein thrombosis or pulmonary embolism within 4 weeks prior to enrollment into the study
• Current abuse of alcohol or illicit drugs
• Treatment with any live/attenuated vaccine in the 7 days prior to enrollment
• Previous treatment with any systemic anticancer therapy within 4 weeks prior to treatment on study

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation

Non-randomized

Model

Sequential

Masking

Open label

Primary purpose

Treatment

Study locations

United States · 11 centers

• University of Miami — Miami
• Biogenix — Miami
• University of Kansas — Kansas City
• University of Kentucky — Lexington
• Mayo Clinic in Rochester, Minnesota — Rochester
• Saint Louis University — St Louis
• Nebraska Cancer Specialists — Omaha
• Ohio State University — Columbus
• … and 3 more centers

Publications

• Fabian D, Levy MS, Piecoro DW, Napier D, Miller RW, Kunos CA. Cancer-associated fibroblast activation protein in Appalachian women with uterine cervix cancer. Front Oncol. 2026 Jun 1;16:1799494. doi: 10.3389/fonc.2026.1799494. eCollection 2026. PMID 42306799

Identifiers

NCT: NCT06710756 · PSV359-001

Primary sources (government registries)

• ClinicalTrials.gov (US NIH)

View this study on ClinicalTrials.gov ↗